肾移植术后患者骨密度水平的调查研究

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (670 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the differences in bone mineral density (BMD) and incidence of bone loss (osteopenia and osteoporosis). Methods Todally 177 renal transplantation recipients (104 males, 73 females) were divided into postmenopausal women, premenopausal women and ＜50-year-old males and ≥50-year-old males. And 250 people with normal physical examination (131 males, 119 females) were included in control group. Bone mineral densities of the lumbar spine, right femoral neck and right hip were assessed by dual X-ray absorptiometry. The transplantation group and the control group were compared in the BMD and incidence of bone loss. Results BMDs of right femoral neck and right hip in all transplantation group were significantly lower than those in the control group (P<0.01).BMD of the lumbar spine in transplantation group of ＜50-year-old males was significantly lower than that in the control group(P<0.01).The incidences of bone loss in males and postmenopausal women were significantly higher than those in the control group(P<0.01). Conclusions BMD in renal transplantation recipients is lower than in normal physical examination. The prevalence of bone loss in renal transplantation recipients is significantly higher than that in normal people. It is suggested that we should on the basis of vitamin and calcium ,select diphosphonate to prevent and treat osteoporosis and bone fracture after renal transplantation.

Key words： renal transplantation bone mineral density osteoporosis osteopenia bone loss

Received: 13 March 2015

ZTFLH:

R589.9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CAO Yong
	WANG Hongyu
	NIU Yujian
	ZHANG Shaofeng
	XU Chun

Cite this article:

CAO Yong,WANG Hongyu,NIU Yujian等. Research of bone mineral density in renal transplantation recipients[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(8): 780-782.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2015/V26/I8/780

[1]	程东瑞,陈惠萍.肾移植后骨病[J].肾脏病与透析肾移植杂志,2010,19(2):187-191.
[2]	赖玮婧,刘芳,付平.慢性肾脏病评估及管理临床实践指南解读——从K/DOQI到KDIGO[J].中国实用内科杂志,2013,33(6):448-453.
[3]	莫挺挺,张文斌,陈黎虬.腰椎骨质增生患者不同部位骨密度检查的临床分析[J].浙江创伤外科,2012,17(5):589-591.
[2]	赖玮婧,刘芳,付平.慢性肾脏病评估及管理临床实践指南解读——从K/DOQI到KDIGO[J].中国实用内科杂志,2013,33(6):448-453.
[3]	莫挺挺,张文斌,陈黎虬.腰椎骨质增生患者不同部位骨密度检查的临床分析[J].浙江创伤外科,2012,17(5):589-591.
[4]	Gupta A K,Huanq M,Prasad G V.Determinants of bone mineral density in stable kidney transplant recipients[J].J Nephrol,2012,25(3):373-383.
[4]	Gupta A K,Huanq M,Prasad G V.Determinants of bone mineral density in stable kidney transplant recipients[J].J Nephrol,2012,25(3):373-383.
[5]	Legg V A. Close look at renal osteodystrophy,nutritional disturbances,and inflammation[J]. Am J Nurs,2005,105(6):40-49.
[6]	Stein E,Ebeling P,Shane E.Post-transplantation osteoporosis[J]. Endocrinol Metab Clin North Am,2007,36(4):937-963.
[5]	Legg V A. Close look at renal osteodystrophy,nutritional disturbances,and inflammation[J]. Am J Nurs,2005,105(6):40-49.
[6]	Stein E,Ebeling P,Shane E.Post-transplantation osteoporosis[J]. Endocrinol Metab Clin North Am,2007,36(4):937-963.
[7]	Varanasi S S,Datta H K.Characterisation of cytosolic FK506 binding protein 12 and its role in modulating expression of Cbfal and osterix in ROS 17/2.8 cells[J].Bone,2005,36(2):243-253.
[7]	Varanasi S S,Datta H K.Characterisation of cytosolic FK506 binding protein 12 and its role in modulating expression of Cbfal and osterix in ROS 17/2.8 cells[J].Bone,2005,36(2):243-253.
[8]	Grotz W.Immunosuppression and skeletal disorders[J]. Transplant Proc,2001,33:992-993.
[8]	Grotz W.Immunosuppression and skeletal disorders[J]. Transplant Proc,2001,33:992-993.
[9]	Smerud K T.A 1-Year Randomized, Double-blind,placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation[J].Transplantation,2012,12(12):3316-3325.
[10]	Abediazar S,Nakhjavani M R. Effect of alendronate on early bone loss of renal transplant recipients[J].Transplant Proc,2011,43(2):565-567.
[9]	Smerud K T.A 1-Year Randomized, Double-blind,placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation[J].Transplantation,2012,12(12):3316-3325.
[10]	Abediazar S,Nakhjavani M R. Effect of alendronate on early bone loss of renal transplant recipients[J].Transplant Proc,2011,43(2):565-567.
[11]	Lan G,Peng L,Xie X,et al. Alendronate is effective to treat bone loss in renal transplantation recipients[J].Transplant Proc,2008 40(10):33496-3498.
[12]	赵海勇,田发明,刘家寅,等.骨质疏松症的药物治疗进展[J].山东医药,2013,53(31):95-97.
[11]	Lan G,Peng L,Xie X,et al. Alendronate is effective to treat bone loss in renal transplantation recipients[J].Transplant Proc,2008 40(10):33496-3498.
[13]	金小岚.钙剂和维生素D在骨质疏松症中的应用[J].中国临床医生,2013,41(6):393-394.
[12]	赵海勇,田发明,刘家寅,等.骨质疏松症的药物治疗进展[J].山东医药,2013,53(31):95-97.
[13]	金小岚.钙剂和维生素D在骨质疏松症中的应用[J].中国临床医生,2013,41(6):393-394.